Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MKS-5 is a standardized botanical extract (phytopharmaceutical) developed by the Malaysian company Medika Natura. Derived from the medicinal plant *Orthosiphon stamineus* (commonly known as Misai Kucing), MKS-5 is being developed for several therapeutic indications. Its most advanced program is for the treatment of urinary tract infections (UTI), which has reached Phase 2 clinical trials. Additionally, the compound is undergoing Phase 1 evaluation for its potential as an analgesic and anti-inflammatory agent, as well as for cardiovascular applications, specifically in the management of hypertension. The extract is designed to provide a consistent, pharmaceutical-grade version of traditional herbal remedies, leveraging the plant's known diuretic and anti-inflammatory properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MKS-5.